Is the reported $400 billion AstraZeneca-Bristol Myers Squibb megamerger a slam dunk or a disaster waiting to happen?
There's a good reason why AstraZeneca tanked when merger rumors hit the Street.
There's a good reason why AstraZeneca tanked when merger rumors hit the Street.